Endothelial cell (EC) surface platelet-activating factor (PAF), together with other cell adhesion molecules including P-selectin, plays an important role in the neutrophil (PMN)-EC adhesion cascade. Human PMN have high and low affinity state PAF receptors, each coupled to separate signal transduction pathways through which different PMN (patho)physiological responses are modulated. Alkyl-PAF is a complete PMN agonist because it interacts with both PAF receptors, triggering full-blown, potentially detrimental PMN activation. Acyl-PAF, on the other hand, is only a partial PMN agonist, preferentially interacting with only the high affinity PAF receptor. On the basis of both thermodynamic and (patho)physiological considerations, it would be expected that modulation of the PMN-EC adhesion cascade by EC surface-associated alkyl-PAF will lead to a significantly different outcome than when acyl-PAF is the predominate species. After EC stimulation with inflammatory mediators, cytokines, enzymes or reactive oxygen species, human EC synthesize both acyl-PAF and alkyl-PAF via the remodelling pathway. Two cytokines implicated in the pathogenesis of endotoxic shock (IL-1alpha and TNFalpha) strongly favor EC synthesis of alkyl-PAF while other inflammatory mediators (ATP, bradykinin and histamine) preferentially induce EC synthesis of acyl-PAF. In view of the preceding, we propose the following two hypotheses: l) EC surface expression of acyl-PAF plays an important role in the PMN-EC adhesion cascade by fostering PMN emigration without fully activating the PMN or causing EC injury; 2) EC surface expression of alkyl-PAF predisposes the vascular endothelium to PMN mediated injury through a greatly amplified PMN-EC adhesion cascade that results in maximal juxtacrine/paracrine priming and activation of EC-adherent PMN. We are now in a unique position to examine these hypotheses because we have recently identified conditions which allow for the preferential synthesis of either acyl-PAF or alkyl-PAF by stimulated human EC. Therefore, we can definitively characterize the normal and detrimental consequences that EC expression of either surface- associated acyl-PAF or alkyl-PAF have on the PMN-EC adhesion cascade. In the proposed studies we will examine the following (patho)physiological responses that are inhibitable by PAF receptor antagonists and occur after adhesion of PMN to EC expressing acyl-PAF or alkyl-PAF on their cell surface: l) PMN-EC adherence; 2) PMN activation; and 3) EC injury (detachment, necrosis, apoptosis). ThroUgh the logical design and straightforward nature of the proposed studies, we will gain a wealth of novel and important information about the (patho)physiological roles that surface-associated EC acyl-PAF and alkyl-PAF play during the interaction of PMN with EC. We are confident that this investigation will greatly expand our understanding of the cell biology of the PAF-dependent mechanisms that modulate both normal PMN trafficking as well as PMN mediated injury of the vascular endothelium, such as in ischemia/reperfusion injury and the microvascular in associated with endotoxic shock.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL022555-20
Application #
2668635
Study Section
Pathology A Study Section (PTHA)
Project Start
1978-04-01
Project End
2000-02-29
Budget Start
1998-03-01
Budget End
2000-02-29
Support Year
20
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of Texas Health Science Center San Antonio
Department
Pathology
Type
Other Domestic Higher Education
DUNS #
800772162
City
San Antonio
State
TX
Country
United States
Zip Code
78229
McManus, L M; Bloodworth, R C; Prihoda, T J et al. (2001) Agonist-dependent failure of neutrophil function in diabetes correlates with extent of hyperglycemia. J Leukoc Biol 70:395-404
McManus, L M; Pinckard, R N (2000) PAF, a putative mediator of oral inflammation. Crit Rev Oral Biol Med 11:240-58
Weintraub, S T; Satsangi, R K; Sprague, E A et al. (2000) Mass spectrometric analysis of platelet-activating factor after isolation by solid-phase extraction and direct derivatization with pentafluorobenzoic anhydride. J Am Soc Mass Spectrom 11:176-81
Pinckard, R N; Prihoda, T J (1996) Alkyl-PAF and acyl-PAF human neutrophil priming for enhanced fMLP- and rC5a-induced superoxide anion production. J Leukoc Biol 59:219-28
Woodard, D S; Mealey, B L; Lear, C S et al. (1995) Molecular heterogeneity of PAF in normal human mixed saliva: quantitative mass spectral analysis after direct derivatization of PAF with pentafluorobenzoic anhydride. Biochim Biophys Acta 1259:137-47
Woodard, D S; Ostrom, K K; McManus, L M (1995) Lipid inhibitors of platelet-activating factor (PAF) in normal human plasma. J Lipid Mediat Cell Signal 12:11-28
Pinckard, R N; Woodard, D S; Showell, H J et al. (1994) Structural and (patho)physiological diversity of PAF. Clin Rev Allergy 12:329-59
Weintraub, S T; Lear, C; Pinckard, R N (1993) Differential electron capture mass spectral response of pentafluorobenzoyl derivatives of platelet activating factor alkyl chain homologs. Biol Mass Spectrom 22:559-64
McManus, L M; Woodard, D S; Deavers, S I et al. (1993) PAF molecular heterogeneity: pathobiological implications. Lab Invest 69:639-50
McManus, L M; Ostrom, K K; Lear, C et al. (1993) Radiation-induced increased platelet-activating factor activity in mixed saliva. Lab Invest 68:118-24

Showing the most recent 10 out of 36 publications